Valeant Issues Statement On Sales Of Company Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Valeant Pharma (VRX) Sees 'Dead Cat Bounce' after CEO Hit with Margin Call
November 6, 2015 12:19 PM ESTValeant Pharma (NYSE: VRX) is pushing to the highs of the session, following earlier news that about 1.3 million shares CEO Mike Pearson had pledged on a loan were sold yesterday due to margins calls.
The news suggests that some of the... More
Valeant Pharma (VRX) 1.3M Shares Pledged on Behalf of Pearson Sold by Goldman Sachs
November 6, 2015 8:03 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) stated today that 1,297,399 shares pledged to Goldman Sachs to secure loans made to chairman and chief executive officer J. Michael Pearson were sold by Goldman Sachs on November 5, 2015. Goldman Sachs held the shares as collateral for loans extended to Pearson.
As disclosed in the company's proxy statement filed on April 22, 2014, the company's board permitted... More
